Weekly Recap | Tempus AI -9.86%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Tempus AI fell 9.86% this week to close at $76.63, underperforming the S&P 500 by roughly 9.59 percentage points. The stock opened the week higher and briefly touched $89.09 before pulling back over three consecutive sessions. Thursday saw a single-day drop of about 6.6%, and Friday held within a $75.80 to $80.305 range. Weekly amplitude reached 15.9%, while average daily volume of around 6.0m shares ran about 7.4% above the 60-day median, pointing to wider disagreement among traders.
The Week
Tempus AI fell 9.86% this week to close at $76.63, underperforming the S&P 500 by roughly 9.59 percentage points. The stock opened the week higher and briefly touched $89.09 before pulling back over three consecutive sessions. Thursday saw a single-day drop of about 6.6%, and Friday held within a $75.80 to $80.305 range. Weekly amplitude reached 15.9%, while average daily volume of around 6.0m shares ran about 7.4% above the 60-day median, pointing to wider disagreement among traders.
Key Events
The company-specific story this week centred on a regulatory approval and academic visibility. On Monday evening, Tempus AI announced FDA clearance for its ECG-MR tool, designed to flag undiagnosed mitral regurgitation. On Thursday, the company said 13 abstracts had been accepted for presentation at the European Society for Medical Oncology Congress 2026. A filing on the same day showed Diagnostics CEO Thomas Edward Schoenherr disposed of roughly $873,885 worth of common shares. Over the weekend an S-4/A registration statement was submitted, a routine securities-related disclosure. No earnings or major partnership news landed during the week, leaving the pullback tied largely to broader pressure on high-multiple growth names.
Analyst Ratings
Among the 20 firms covering the stock, 8 rate it buy, 2 rate it overweight, 9 rate it hold, and 1 rates it sell. The consensus rating is buy, with a consensus target of $70.05556, about 8.58% below the latest price. The target range is wide, from $35 to $100, indicating a meaningful split in valuation views. Tempus ranks 8th within a group of 54 life science tools and services companies. The rating mix leans constructive, but a target below spot shows how divided analysts are on how much premium the stock should carry.
The Week Ahead
No company earnings are scheduled for next week. On Monday the US S&P Global services PMI final and ISM non-manufacturing PMI will be released; Tuesday brings international trade data; Wednesday has EIA crude inventory figures. These releases could shift discount-rate expectations for growth stocks at a time when risk appetite has already retreated. Whether sentiment stabilises or extends the pullback is the main thing to watch.
In Short
Tempus AI recorded a near double-digit weekly decline despite an FDA clearance and ESMO academic presence, which suggests the market is trimming its appetite for richly valued growth names. The rating structure is mixed: 10 firms at buy or overweight against 9 at hold. The latest daily capital snapshot shows the heaviest outflow on the small-lot side, with large-lot inflow and outflow nearly matched. The valuation remains stretched at 30.90x P/B and negative P/E, leaving the shares highly sensitive to shifts in sentiment and discount rates. The key question is whether upcoming macro data stabilises growth-stock pricing and whether Tempus can convert its regulatory and academic wins into sustained revenue growth.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.